ArriVent BioPharma Inc.
AVBP | NASDAQ
$29.74
+$0.84 (+2.91%)
At close: Sep 21, 2026, 4:00 PM ET
$29.70
-$0.04 (-0.13%)
Pre-market:
Sep 22, 2026, 5:06 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a |
Operating Income | -177.53M | -94.31M | -74.59M | -36.91M | -8.7M |
Interest Income | 11.23M | 13.82M | 5.26M | n/a | n/a |
Pretax Income | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Net Income | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Selling & General & Admin | 24.18M | 15.3M | 9.71M | 6.47M | 2.26M |
Research & Development | 153.35M | 79M | 64.88M | 30.43M | 6.43M |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 177.53M | 94.31M | 74.59M | 36.91M | 8.7M |
Interest Expense | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 177.53M | 94.31M | 74.59M | 36.91M | 8.7M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 38.46M | 31.47M | 31.96M | 33.49M | 1.28M |
Shares Outstanding (Diluted) | 38.46M | 31.47M | 31.96M | 33.49M | 1.28M |
EPS (Basic) | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
EPS (Diluted) | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
EBITDA | -166.31M | -80.49M | -69.33M | n/a | -51.61M |
EBIT | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Depreciation & Amortization | n/a | n/a | n/a | 36.91M | n/a |
Add to Watchlist
Select watchlists to add or remove AVBP